![]() |
|
|
Vol. 30, Issue 11, 1201-1205, November 2002
Laboratory of Pharmacology and Toxicology, Graduate School of
Pharmaceutical Sciences, Chiba University, Chiba-shi (T.S., M.H., K.K.,
H.T., Y.Y., M.T., K.C.); Third Biological Section, Department of
First Forensic Science, National Research Institute of Police Sciences,
Kashiwa-shi (T.S.), and Asahi Technoglass, Funabashi-shi, Chiba, Japan
(H.T.)
CYP2D6 is a polymorphic enzyme that catalyzes the oxidation of
various drugs. At least 40-mutant alleles of CYP2D6 have
been reported. CYP2D6*14, which is one of them found in
Asian populations, causes deficient activity of CYP2D6. Four amino acid
substitutions, P34S, G169R, R296C, and S486T, are present in the
protein encoded by CYP2D6*14 (CYP2D6 14). Among them,
G169R is thought to be a definitive substitution because it is unique
to CYP2D6 14. However, a previous study showed that the activity of
G169R-substituted CYP2D6 was about 40% of wild-type CYP2D6, suggesting
that a combination of G169R and other substitutions may be required to
abolish the activity of CYP2D6. In the present study, we examined the
effects of combined substitutions of G169R and P34S on the functional properties of CYP2D6 and compared them with those of a single substitution of G169R or P34S using a cDNA expression system of V79
cells. The results showed that a combined substitution of G169R and
P34S reduced the activities of CYP2D6 to less than the detection limit
of our analytical method for bufuralol 1'-hydroxylation and
dextromethorphan O-demethylation. However, these
activities were not completely abolished by a single substitution of
P34S or G169R. The findings suggest that simultaneous substitution of
G169R and P34S is crucial for almost completely abolishing the activity
of CYP2D6 at least in V79 cells, although whether the absence of
metabolism is due to the absence of functional protein or catalytic
incompetency remains unclear because the levels of CYP2D6 protein
expressed in V79 cells were too low to be determined by difference
CO-reduced spectra.
This article has been cited by other articles:
![]() |
K. Sakuyama, T. Sasaki, S. Ujiie, K. Obata, M. Mizugaki, M. Ishikawa, and M. Hiratsuka Functional Characterization of 17 CYP2D6 Allelic Variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57) Drug Metab. Dispos., December 1, 2008; 36(12): 2460 - 2467. [Abstract] [Full Text] [PDF] |
||||